ArticleMolecular therapy. Methods & clinical development2018
Improved Expansion and
Article in Molecular therapy. Methods & clinical development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.Nature reviews. Cancer · 2026Review
- Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model.Bioactive materials · 2026Article
- Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.Research square · 2026Article
- Human serum influences functional plasticity and transcriptomic landscape of γδ T cellsFrontiers in immunology · 2026Article
- Method for generation and ex vivo expansion of genetically edited mouse Tregs.Journal of leukocyte biology · 2025Article
- Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Cost-effective strategies for CAR-T cell therapy manufacturing.Molecular therapy. Oncology · 2025Review
- Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium.International journal of molecular sciences · 2025Article
- Accelerating Diverse Cell-Based Therapies Through Scalable Design.Annual review of chemical and biomolecular engineering · 2024Review
- Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.Annals of laboratory medicine · 2024Review
- ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights.Frontiers in immunology · 2024Review
- A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.Frontiers in immunology · 2024Article
- Use of serum-free media for peripheral blood mononuclear cell culture and the impact on T and B cell readouts.Frontiers in toxicology · 2024Article
- The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.Biomarker research · 2023Review
- Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality.Scientific reports · 2023Article
- Optimization of Peripheral Blood Mononuclear Cell Processing for Improved Clinical ELISpot Assay Performance.The AAPS journal · 2023Article
- Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective.Cells, tissues, organs · 2023Review
- Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used.Annals of laboratory medicine · 2022Article
- Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.Science translational medicine · 2022Article
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.Nature medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Improvements to T cell culture systems that promote long-term engraftment and function of adoptively transferred T cells will likely result in superior clinical benefit to more individuals. To this end, we recently developed a chemically defined cell culture medium that robustly expands all T cell subsets in the absence of human serum. Using a humanized mouse model, we observed that T cells expanded in the absence of human serum provided durable control of tumors, whereas T cells expanded in medium supplemented with human serum only mediated transient control of tumor growth. Importantly, our new medium effectively expanded more differentiated T cells from multiple myeloma patients in the absence of serum. These patient-derived T cells were also able to provide durable control of B cell tumors
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.